Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
Schmid S, Russell ZR, Yamashita AS, West ME, Parrish AG, Walker J, Rudoy D, Yan JZ, Quist DC, Gessesse BN, Alvinez N, Cimino PJ, Kumasaka DK, Parchment RE, Holland EC, Szulzewsky F. Schmid S, et al. Among authors: parchment re. bioRxiv [Preprint]. 2024 Mar 26:2024.03.13.584849. doi: 10.1101/2024.03.13.584849. bioRxiv. 2024. PMID: 38558981 Free PMC article. Preprint.
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP. Mittra A, et al. Among authors: parchment re. Cancer Chemother Pharmacol. 2024 Mar;93(3):177-189. doi: 10.1007/s00280-023-04600-0. Epub 2023 Nov 27. Cancer Chemother Pharmacol. 2024. PMID: 38010394 Free PMC article. Clinical Trial.
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Chen AP, et al. Among authors: parchment re. N Engl J Med. 2023 Sep 7;389(10):911-921. doi: 10.1056/NEJMoa2303383. N Engl J Med. 2023. PMID: 37672694 Free PMC article. Clinical Trial.
Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo.
Tyurina YY, Kapralov AA, Tyurin VA, Shurin G, Amoscato AA, Rajasundaram D, Tian H, Bunimovich YL, Nefedova Y, Herrick WG, Parchment RE, Doroshow JH, Bayir H, Srivastava AK, Kagan VE. Tyurina YY, et al. Among authors: parchment re. Redox Biol. 2023 May;61:102650. doi: 10.1016/j.redox.2023.102650. Epub 2023 Feb 28. Redox Biol. 2023. PMID: 36870109 Free PMC article.
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team. Manzo J, et al. Among authors: parchment re. Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18. Cancer Chemother Pharmacol. 2022. PMID: 35435472 Free PMC article. Clinical Trial.
Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis.
Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, Roszik J, Ferry-Galow KV, Parchment RE, Liu X, Andresson T, Duncan G, Kurie JM, Rodriguez-Canales J, Liu X, Dmitrovsky E. Chen Z, et al. Among authors: parchment re. Cancer Biol Ther. 2022 Dec 31;23(1):265-280. doi: 10.1080/15384047.2022.2054242. Cancer Biol Ther. 2022. PMID: 35387560 Free PMC article.
ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide.
El Touny LH, Hose C, Connelly J, Harris E, Monks A, Dull AB, Wilsker DF, Hollingshead MG, Gottholm-Ahalt M, Alcoser SY, Mullendore ME, Parchment RE, Doroshow JH, Teicher BA, Rapisarda A. El Touny LH, et al. Among authors: parchment re. Oncotarget. 2021 Oct 12;12(21):2114-2130. doi: 10.18632/oncotarget.28090. eCollection 2021 Oct 12. Oncotarget. 2021. PMID: 34676045 Free PMC article.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Kummar S, et al. Among authors: parchment re. Invest New Drugs. 2021 Dec;39(6):1577-1586. doi: 10.1007/s10637-021-01138-x. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180036 Free PMC article. Clinical Trial.
99 results